The biology of pediatric acute megakaryoblastic leukemia.
Blood
; 126(8): 943-9, 2015 Aug 20.
Article
em En
| MEDLINE
| ID: mdl-26186939
ABSTRACT
Acute megakaryoblastic leukemia (AMKL) comprises between 4% and 15% of newly diagnosed pediatric acute myeloid leukemia patients. AMKL in children with Down syndrome (DS) is characterized by a founding GATA1 mutation that cooperates with trisomy 21, followed by the acquisition of additional somatic mutations. In contrast, non-DS-AMKL is characterized by chimeric oncogenes consisting of genes known to play a role in normal hematopoiesis. CBFA2T3-GLIS2 is the most frequent chimeric oncogene identified to date in this subset of patients and confers a poor prognosis.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Megacarioblástica Aguda
Limite:
Child
/
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article